CN101538247A - Alkaloid compound and preparation method thereof - Google Patents

Alkaloid compound and preparation method thereof Download PDF

Info

Publication number
CN101538247A
CN101538247A CN200810010678A CN200810010678A CN101538247A CN 101538247 A CN101538247 A CN 101538247A CN 200810010678 A CN200810010678 A CN 200810010678A CN 200810010678 A CN200810010678 A CN 200810010678A CN 101538247 A CN101538247 A CN 101538247A
Authority
CN
China
Prior art keywords
compound
streptomycete
cgmcc
obtains
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200810010678A
Other languages
Chinese (zh)
Other versions
CN101538247B (en
Inventor
张怡轩
吴春福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CN200810010678A priority Critical patent/CN101538247B/en
Publication of CN101538247A publication Critical patent/CN101538247A/en
Application granted granted Critical
Publication of CN101538247B publication Critical patent/CN101538247B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention belongs to the technical field of medicaments and discloses an alkaloid compound and a preparation method thereof. The compound is obtained by steps of the strain culture and fermentation of streptomycete YL05A-1070(CGMCC No.2362) screened from soil on the slope of Duyang Mountain in Taihua County, Guanxi province, China, the filtration, extraction, adsorption elution and freeze drying of the fermentation liquor, and the like. The purity of the compound reaches more than 95 percent. The compound and pharmaceutically acceptable salts thereof including sulfate, hydrochloride and organic acid salt have the capacity of suppressing A549 cells, HGC-2 cells, HGC-27 cells and MCF-7 cells obviously. This capacity gives an indication that the compound has antitumor activity and can be used for developing antitumor drugs.

Description

A kind of alkaloid compound and preparation method thereof
Technical field
The invention belongs to medical technical field, relate to alkaloid compound and preparation method thereof, be specifically related to a kind of compound and its pharmacy acceptable salt with anti-tumor activity; The present invention also relates to the microbial fermentation processes and the purposes of this compound on the manufacturing antitumor drug of this compound.
Background technology
Tumour is the frequently-occurring disease and the common disease of a class serious threat human health, and M ﹠ M is in rising trend always, has become first deadly disease at present.The cancer mortality front three is liver cancer, cancer of the stomach, lung cancer, and China is one of liver cancer country occurred frequently in the world, and sickness rate is about 1/0,000.Liver cancer is in the situation of the effective medicine of a kind of famine so far, owing to liver cancer is lacked effective control method, patient's prognosis extreme difference.Except that but 5 annual survival rates of early stage patient with operation reach 80~90%, can not patient with operation, the mean survival time to paresthesia epilepsy has only 3~4 months, and average 5 annual survival rates of the whole liver cancer cases of developing country only are about 5%.In addition, in, a thorny problem of advanced liver cancer clinical treatment is pain caused by cancer, after the patient finally brings into use morphine class analgesic, because its serious drug dependence, have only the increase that continues rapidly by dosage, just can reach the lenitive effect, and continuously heavy dose of analgesic uses, increased the weight of the burden of liver again, thereby the grade malignancy of cancer is further aggravated.Therefore, the new antitumor class medicine of exploitation just seems very urgent and necessary.
Summary of the invention
One object of the present invention is to provide a kind of new antitumor class medicine A that is used for the treatment of tumor disease, and its molecular formula is C 7H 9FN 2O 4, molecular weight is 216, chemical structural formula is suc as formula shown in (I).Fusing point 141-143 ℃, the outward appearance powder that is white in color, it is hydrochloride, vitriol or organic salt at pharmacy acceptable salt.
The structure of the compd A that the present invention relates to adopts the method for nucleus magnetic resonance, spectroscopy such as infrared to determine.
Another object of the present invention provides the fermentation bacterial classification and the preparation method of this antitumor antibiotics.
Through preliminary test, compd A is at the external growth that can effectively suppress kinds of tumor cells, its IC 50In 0.9-56.7 μ mol/L scope, has notable antitumor activity.
Figure A20081001067800031
Formula 1
Indole ketone compound A of the present invention separates to extract in the fermenting culture that obtains false light gray streptomycete Y05A-1070 (CGMCC No.:2362) the soil on slope, Yangshan from Guangxi province Tai Hua county to obtain, and preparation method's concrete steps are as follows:
(1) the slant culture method of streptomycete Y05A-1070 (CGMCC No.:2362): slant medium is formed (1L): Zulkovsky starch 20g, NaCl 0.5g, KNO 31g, K 2HPO 40.5g, FeSO 40.01g, MgSO 4.7H 2O 0.5g, agar part 20g, pH 7.0.28-30 ℃, cultivated 7 days.
(2) the seed liquor cultural method of streptomycete Y05A-1070 (CGMCC No.:2362): seed culture medium is formed (1L): analysis for soybean powder 5~15g, yeast extract paste 3~7g, glucose 10~30g, starch 10~30g, K 2HPO 40.1-1.0g, (NH 4) 2SO 40.1-3.0g, MgSO 4.7H 2O 0.1-0.5g, CaCO 30.1-5.0g pH 7.2.Triangle shakes bottled amount 20-60%, rotating speed 100-250 rev/min, 28-32 ℃, cultivates 20-48 hour.
(3) fermentation process of streptomycete Y05A-1070 (CGMCC No.:2362): fermention medium is formed (1L): peanut powder 10-25g, yeast extract paste 5-30g, glucose 0.5-30g, peptone 0.1-10g, (NH 4) 2SO 40.1-10g, KCl 0.1-3g, pH 7.0.Fermentor tank loading amount 20-60%, inoculum size 3-12%, 28-32 ℃, cultivated 5-7 days by rotating speed 100-250 rev/min.After the fermentation ends, tunning obtains mycelium and ferment filtrate two portions after filtering through plate-and-frame filter press.
(4) the mycelium part that obtains of step (3),
(a) with clear water wash 2-3 all over after, squeeze out most of moisture, airing under the normal temperature;
(b) mycelium with methanol extraction for several times, the extract concentrating under reduced pressure obtains medicinal extract;
(c) medicinal extract disperses with distilled water, with ethyl acetate extraction for several times, separates and recrystallization purifying through 100-200 order silicagel column (moving phase is chloroform-ethyl acetate gradient elution), obtains compd A.
The external growth that can effectively suppress kinds of tumor cells of compound through the present invention's preparation has notable antitumor activity.
Used false light gray streptomycete (Streptomyces pseudogriseolus) Y05A-1070 of the present invention has been preserved in China Committee for Culture Collection of Microorganisms common micro-organisms center (Datun Road, Chaoyang District, Beijing City Institute of Microorganism, Academia Sinica), preserving number is CGMCC No.:2362), preservation day is on January 25th, 2008.
Embodiment
The preparation of embodiment 1 compd A
(1) the slant culture method of streptomycete Y05A-1070 (CGMCC No.:2362): slant medium is formed (1L): Zulkovsky starch 20g, NaCl 0.5g, KNO 31g, K 2HPO 40.5g, FeSO 40.01g, MgSO 4.7H 2O 0.5g, agar part 20g, pH 7.0.28-30 ℃, cultivated 7 days.
(2) the seed liquor cultural method of streptomycete Y05A-1070 (CGMCC No.:2362): seed culture medium is formed (1L): analysis for soybean powder 5~15g, yeast extract paste 3~7g, glucose 10~30g, starch 10~30g, K 2HPO 40.1-1.0g, (NH 4) 2SO 40.1-3.0g, MgSO 4.7H 2O 0.1-0.5g, CaCO 30.1-5.0g pH 7.2.Triangle shakes bottled amount 20-60%, rotating speed 100-250 rev/min, 28-32 ℃, cultivates 20-48 hour.
(3) fermentation process of streptomycete Y05A-1070 (CGMCC No.:2362): fermention medium is formed (1L): peanut powder 10-25g, yeast extract paste 5-30g, glucose 0.5-30g, peptone 0.1-10g, (NH 4) 2SO 40.1-10g, KCl 0.1-3g, pH 7.0.Fermentor tank loading amount 20-60%, inoculum size 3-12%, 28-32 ℃, cultivated 5-7 days by rotating speed 100-250 rev/min.After the fermentation ends, tunning obtains mycelium and ferment filtrate two portions after filtering through plate-and-frame filter press
(4) the mycelium part that obtains of step (3),
(a) with clear water wash 2-3 all over after, squeeze out most of moisture, airing under the normal temperature;
(b) mycelium with methanol extraction for several times, the extract concentrating under reduced pressure obtains medicinal extract;
(c) medicinal extract disperses with distilled water, with ethyl acetate extraction for several times, separates and recrystallization purifying through 100-200 order silicagel column (moving phase is chloroform one ethyl acetate gradient elution), obtains compd A.
The experimental data of compd A: outward appearance is a white powder, m.p.141-143.Be slightly soluble in benzene, chloroform, ether equal solvent, water-soluble, ethanol, methyl alcohol.MS(m/z):216。IR υ/cm -1(KBr):1761(υ C=O),1724(υ C=O),1657(υ C=O)。 1H-NMR(CDCl 3)δ:1.31(3H,t,J=7.2Hz,-CH 3),4.26(2H,q,J=7.2HZ,-COOCH 2-),4.68(2H,s,-CH 2N<C-9),7.32(1H,d,C-H,J=3.0Hz),9.93(1H,br s,H-N<)。
The anti-tumor activity of embodiment 2MTT reduction method detection compound A
1. material:
1.1 four Cuo salt (MTT): (3-(4 for phosphate buffered saline buffer (PBS) the dissolving MTT of usefulness 0.01M, 5-dimethythiazol z-yl) 2,5-diphenyltetrazolium bromide, SIGMA) final concentration 5mg/mL, filtration sterilization, 4 ℃ keep in Dark Place after the packing.
1.2 the preparation of target cell (is example with the A549 cell): take out the frozen pipe of human lung carcinoma cell line A549 cell from liquid nitrogen container, insert rapidly in 37 ℃ of water-baths, do not stop to shake and make it to dissolve rapidly, aseptic technique moves in the centrifuge tube; To 10mL, the centrifugal 5s of 1000rpm abandons supernatant to add full nutrient solution (RPMI1640 (Gibcol BRL company) that contains 10% calf serum); Repeat above operation once; Move in the culturing bottle 5%CO after making the cell mixing with the piping and druming of full nutrient solution 2, 37 ℃ of cultivations; The observation of cell growing state is in time changed nutrient solution, divides bottle.The cell in vegetative period of taking the logarithm, trysinization is adjusted cell count to 1x10 5/ mL; Cell suspension is joined in 96 orifice plates, and each hole adds A549 cell 100 μ L (1x10 5/ mL), 5%CO 2, cultivate 8hr for 37 ℃.Add different concns B6-9 (using full nutrient solution preparation) solution 100 μ L, contrast adds full nutrient solution 100 μ L, continues to cultivate 48hr.Every hole adds each 10 μ L of MTT solution, continues to cultivate 4hr.Remove nutrient solution, every hole adds DMSO100 μ L, and the 5-10min that vibrates gently makes the particle dissolving.Use the enzyme linked immunological instrument to measure every hole OD value under the 570nm.Calculate tumor cell destruction and inhibiting rate,, try to achieve IC with the logarithm mapping of inhibiting rate to drug level 50Lung cancer cell line A549, hepatoma cell strain HepG-2, stomach cancer cell line HGC-27, the test method of breast cancer cell strain MCF-7 is the same.
The average OD value that the average OD value that tumor cell destruction %=[(control group is measured-dosing group is measured)/the average OD value of control group mensuration] * 100%
1.3 experimental result
Experimental result shows that compd A all can effectively suppress lung cancer cell line A549, hepatoma cell strain HepG-2, stomach cancer cell line HGC-27, the growth of breast cancer cell strain MCF-7.Compd A is to the IC of these cancer cells 50Value (μ mol/L) sees Table 1.
The cell in vitro poison test-results (IC of table 1B6-9 50μ mol/L)
Cell strain Compd A
Lung cancer cell line A549 0.9
Hepatoma cell strain HepG-2 15.3
Stomach cancer cell line HGC-27 31.0
Breast cancer cell strain MCF-7 56.7

Claims (4)

1. alkaloid compound, it is characterized in that: the structural formula of this compound is shown in (A): its molecular formula is C 7H 9FN 2O 4, molecular weight is 216, outward appearance is a white crystals.
Figure A2008100106780002C1
2. a kind of alkaloid compound according to claim 1 is characterized in that: comprise that also this compound is being vitriol, hydrochloride and organic acid salt at pharmacy acceptable salt.
3. the preparation method of an alkaloid compound as claimed in claim 1, it is characterized in that: this method comprises that cultivation can produce the culture condition of described antibiotic streptomycete Y05A-1070 (CGMCCNo.2362), and from fermented liquid, reclaim resulting microbiotic, its concrete steps are as follows:
(1) the slant culture method of streptomycete Y05A-1070 (CGMCC No.2362): slant medium is formed (1L): Zulkovsky starch 20g, NaCl 0.5g, KNO 31g, K 2HPO 40.5g, FeSO 40.01g, MgSO 4.7H 2O 0.5g, agar part 20g, pH 7.0.28-30 ℃, cultivated 7 days;
(2) the seed liquor cultural method of streptomycete Y05A-1070 (CGMCC No.2362): seed culture medium is formed (1L): analysis for soybean powder 5~15g, yeast extract paste 3~7g, glucose 10~30g, starch 10~30g, K 2HPO 40.1-1.0g, (NH 4) 2SO 40.1-3.0g, MgSO 4.7H 2O 0.1-0.5g, CaCO 30.1-5.0g pH 7.2.Triangle shakes bottled amount 20-60%, rotating speed 100-250 rev/min, 28-32 ℃, cultivates 20-48 hour;
(3) fermentation process of streptomycete Y05A-1070 (CGMCC No.2362): fermention medium is formed (1L): peanut powder 10-25g, yeast extract paste 5-30g, glucose 0.5-30g, peptone 0.1-10g, (NH 4) 2SO 40.1-10g, KCl 0.1-3g, pH 7.0.Fermentor tank loading amount 20-60%, inoculum size 3-12%, 28-32 ℃, cultivated 5-7 days by rotating speed 100-250 rev/min.After the fermentation ends, tunning obtains mycelium and ferment filtrate two portions after filtering through plate-and-frame filter press;
(4) the mycelium part that obtains of step (3),
(a) with clear water wash 2-3 all over after, squeeze out most of moisture, airing under the normal temperature;
(b) mycelium with methanol extraction for several times, the extract concentrating under reduced pressure obtains medicinal extract;
(c) medicinal extract disperses with distilled water, with ethyl acetate extraction for several times, separates and recrystallization purifying through 100-200 silicagel column (moving phase is chloroform one ethyl acetate gradient elution), obtains compd A.
4. the application of alkaloid compound (A) in the medicine of preparation inhibition tumour.
CN200810010678A 2008-03-17 2008-03-17 Preparation method of alkaloid compound Expired - Fee Related CN101538247B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200810010678A CN101538247B (en) 2008-03-17 2008-03-17 Preparation method of alkaloid compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200810010678A CN101538247B (en) 2008-03-17 2008-03-17 Preparation method of alkaloid compound

Publications (2)

Publication Number Publication Date
CN101538247A true CN101538247A (en) 2009-09-23
CN101538247B CN101538247B (en) 2012-08-29

Family

ID=41121663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200810010678A Expired - Fee Related CN101538247B (en) 2008-03-17 2008-03-17 Preparation method of alkaloid compound

Country Status (1)

Country Link
CN (1) CN101538247B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104911121A (en) * 2015-04-07 2015-09-16 浙江省农业科学院 Aspergillus awamori and its microbe inocula and application thereof
CN110467574A (en) * 2019-07-17 2019-11-19 蒋周倩 Compound adamantane acid -5 FU 5 fluorouracil methyl esters synthesis and application
CN113292574A (en) * 2020-02-21 2021-08-24 四川大学 Chiral polycyclic tropane compounds, preparation method and application thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104911121A (en) * 2015-04-07 2015-09-16 浙江省农业科学院 Aspergillus awamori and its microbe inocula and application thereof
CN104911121B (en) * 2015-04-07 2017-12-15 浙江省农业科学院 False light gray streptomycete and its microbial bacterial agent and application
CN110467574A (en) * 2019-07-17 2019-11-19 蒋周倩 Compound adamantane acid -5 FU 5 fluorouracil methyl esters synthesis and application
CN113292574A (en) * 2020-02-21 2021-08-24 四川大学 Chiral polycyclic tropane compounds, preparation method and application thereof

Also Published As

Publication number Publication date
CN101538247B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
CN103865808A (en) Novel anti-tumor application of penicillium enol A1 from penicillium citrinum
CN103865809A (en) Novel anti-tumor application of penicillium enol B1 from penicillium citrinum
CN102731365B (en) Hericium erinaceum biological micro-molecules for inhibiting helicobacter pylori and use of hericium erinaceum biological micro-molecules in treatment of digestive tract diseases
CN101628931B (en) Antitumor antibiotics, pharmaceutically acceptable salts thereof, preparation method thereof and use thereof
CN101538247B (en) Preparation method of alkaloid compound
CN104531540A (en) Antitumor application of penicillium enol A2 from penicillium citrinum
CN102030753B (en) Prenylated indole alkaloids and preparation method and application thereof
CN105017203A (en) Azaphilones derivative compound from marine fungi as well as preparation method and application of azaphilones derivate compound
CN104592082A (en) Method for preparing penicillium enol D2 derived from Penicillium citrinum and application of penicillium enol D2
CN101280333B (en) Method for preparing penicillium antibacterial peptide from grey rose penicillium
CN104031051A (en) Diketopiperazines and preparation method and application thereof
CN102051394A (en) Preparation method and application of sulfo-diketopiperazine compounds
CN102531906B (en) Application of natural compound P21 in inhibition of reproductive growth of tumor cell
CN1212387C (en) Fine rod bundle spore SX-1 separated and cultured from cordyceps and its saparation, culture process and use
CN101538239B (en) Antitumor antibiotic and preparation method thereof
CN112300243A (en) Cyclopeptide compound and preparation method and application thereof
CN100430361C (en) Quinone compounds and its preparation method and antineoplastic use
CN101362745A (en) Xanthenes compounds, preparation method and application thereof in antitumor
JP3719689B2 (en) Novel substance triprostatin, process for producing the same, cell cycle inhibitor and antitumor agent
CN104211780A (en) Cyclic depsipeptides compound, preparation method and purpose thereof
CN104211670A (en) Alkyl pyranone compound and preparation process and application
US20100041896A1 (en) Macrolide compound with bis-oxazoly
CN102584680A (en) Aspochalasin U and preparing method and application thereof
CN102911877A (en) Marine fungi cladosporium sphaerospermum and application thereof
CN110218174B (en) Compound and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120829

Termination date: 20170317

CF01 Termination of patent right due to non-payment of annual fee